Clinical trials
Locally Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting locally advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 3,558 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06663839RecruitingPhase 1
Study of NILK-2301 for advanced colorectal cancer
This trial tests a new drug called NILK-2301 for people with colorectal cancer that has spread or cannot be removed. It is for those who have already tried at least one other treatment and have relatively small tumors.
BarcelonaAges 18 years+ - NCT06783348RecruitingPhase 2
Radioactive treatment for advanced kidney cancer
This trial tests a radioactive treatment (called radiopharmaceutical) that targets a protein called PSMA on kidney cancer cells. It is for people with advanced clear cell kidney cancer that has already been treated with immunotherapy and targeted therapy.
CaenAges 18–100 - NCT06856187RecruitingPhase 2
Second-line chemo plus TAS-102 combo for advanced colorectal cancer
This trial tests adding a new drug combo (TAS-102 and bevacizumab) to standard second-line treatment for advanced colorectal cancer, followed by local treatments. It may help if your first treatment stopped working and you are otherwise in good health.
Shanghai, Shanghai MunicipalityAges Any age - NCT07042685RecruitingPhase 2
5-FU and Fruquintinib for advanced colorectal cancer
This trial tests a combination of two drugs (5-FU and fruquintinib) in people with advanced colorectal cancer that cannot be removed by surgery or has spread. It is for those who have not had chemotherapy before.
Houston, TexasAges 18 years+ - NCT07066917Recruiting
Breast cancer treatment response study
This study looks at how well newer treatments work for advanced or metastatic breast cancer and why some people respond better than others. It is for anyone with HR-positive, HER2-positive/low, or triple-negative breast cancer who has started at least one treatment cycle.
AthensAges 18 years+ - NCT07071337RecruitingPhase 3
Study of SKB264 vs chemo for HR+/HER2- breast cancer after hormone therapy
This trial tests a new drug, SKB264, against standard chemotherapy for people with a common type of breast cancer (HR+/HER2-) that has spread and stopped responding to hormone therapy. It may offer a new option if you haven't had chemotherapy for advanced disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07182721RecruitingPhase 2
Study of SKB264 plus Inetetamab for advanced HER2+ breast cancer after T-DXd
This trial is testing a combination of two targeted therapies, SKB264 and Inetetamab, for people with advanced HER2-positive breast cancer that has kept growing after treatment with T-DXd and other HER2-targeted therapies. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT07500220RecruitingPhase 1/Phase 2
Dual-target CAR-NK cell therapy for advanced liver cancer
This trial tests a new cell therapy made from natural killer (NK) cells that are engineered to attack two targets (GPC3 and B7-H3) found on liver cancer cells. It may be an option for people with advanced liver cancer who have already tried standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07595172RecruitingPhase 1/Phase 2
New drug combination for advanced pancreatic cancer
This study tests whether combining three treatments—NALIRIFOX (chemotherapy), Adebrelimab (an immune-boosting antibody), and PULSAR (radiation)—can help people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if this combination works better than standard care.
Chengdu, SichuanAges 18–75 - NCT05508906RecruitingPhase 1
Test drug OP-1250 with other medicines in ER-positive breast cancer
This Phase 1b study tests OP-1250 (palazestrant) combined with other targeted medicines for ER-positive, HER2-negative advanced or metastatic breast cancer. It mainly looks at safety and correct dosing, but may also help shrink tumors or slow growth.
Gilbert, ArizonaAges 18 years+ - NCT06008054RecruitingPhase 2
New drug combo for advanced gastrointestinal cancers
This trial tests two new drugs (BL-B01D1 and SI-B003) alone or with a standard immunotherapy for advanced gastrointestinal cancers. The goal is to see if these combinations shrink tumors and are safe.
Beijing, Beijing MunicipalityAges 18–75 - NCT06215950RecruitingPhase 1
CAR-T cell therapy for advanced gynecologic cancer with CD70 protein
This trial tests a new treatment called CAR-T cells that target a protein called CD70 found on some gynecologic cancer cells. It is for people whose cancer has advanced or spread and has not responded to or stopped responding to standard treatments.
Wuhu, AnhuiAges 18 years+ - NCT04005690RecruitingEarly Phase 1
Targeted drug treatment for pancreatic cancer using pathway changes
This early-phase trial tests how well targeted medicines (and possibly an immunotherapy drug) work for people with pancreatic cancer that can’t be fully removed with surgery or has spread. It also looks at whether the treatment is safe and can shrink or control tumors by blocking specific cancer pathways.
Portland, OregonAges 18 years+ - NCT06500052RecruitingPhase 1
Study of BL-M17D1 for HER2-positive or low-expression digestive tract and other solid tumors
This trial tests a new drug called BL-M17D1 for people with advanced or metastatic HER2-positive or low-expression gastrointestinal cancer and other solid tumors. The goal is to see if it is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT07002177RecruitingPhase 1/Phase 2
Combination therapy study for ER+/HER2- breast cancer
This trial tests a new drug called FWD1802 combined with other treatments for people with a certain type of advanced breast cancer (ER-positive, HER2-negative). It aims to find better options if standard treatments have stopped working or aren't suitable.
ShanghaiAges 18–75 - NCT05975593Recruiting
Study how radiation affects tumor biology in cervical or pancreatic cancer
This study looks at how radiotherapy changes the tumor environment, using lab samples collected during treatment. It may help researchers understand why radiation works differently for different people and could improve future treatment planning.
St Louis, MissouriAges 18 years+ - NCT07145450RecruitingPhase 1/Phase 2
T-cell therapy for advanced pancreatic cancer with KRAS mutations
This trial tests a personalized T-cell therapy designed to target pancreatic cancer cells that have a specific KRAS mutation (G12V or G12D). It is for people whose cancer has spread or is locally advanced and who have already benefited from standard treatments.
CopenhagenAges 18 years+ - NCT07564232RecruitingPhase 1
LNK001 for Advanced Kidney Cancer After Prior Treatments
This Phase 1 trial tests a new cell therapy called LNK001 in patients with advanced clear-cell kidney cancer that has progressed despite prior immunotherapy and targeted drugs. The therapy is designed to recognize and attack cancer cells by targeting a protein called CAIX.
Houston, TexasAges 18–70 - NCT06253494RecruitingPhase 1/Phase 2
Combination therapy trial for advanced endometrial cancer
This trial tests a combination of three drugs (pembrolizumab, lenvatinib, and an immune booster called N-803) plus a personalized vaccine made from your own cells, all aimed at helping your immune system fight advanced or metastatic endometrial cancer that has HER2 protein on its surface.
Bethesda, MarylandAges 18–120 - NCT06738966RecruitingPhase 1
BL0175 for advanced HR-positive breast or gynecologic cancer
This trial tests a new drug called BL0175 for women with certain types of advanced breast, ovarian, or endometrial cancer that have stopped responding to hormone therapy. The goal is to see if the drug can help shrink tumors or slow down the cancer.
Changchun, JilinAges 18 years+ - NCT07182149RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called NRM-823 for people with several types of advanced cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
Denver, ColoradoAges 18 years+ - NCT07469683RecruitingPhase 2
Combination therapy for advanced kidney cancer after first-line treatment
This trial tests a combination of two drugs (SLC-3010 and axitinib) versus axitinib alone for people with advanced clear cell kidney cancer that has progressed after initial treatment. It aims to see if the combination is safer and more effective.
SeoulAges 19 years+ - NCT07542262Enrolling by invitationPhase 2
Low-dose immunotherapy for advanced colorectal and stomach cancer
This study tests a lower dose of immunotherapy in patients with colorectal or stomach cancer that has spread or cannot be removed by surgery. The cancer must have a specific genetic feature (MSI/dMMR). The goal is to see if this approach works well with fewer side effects.
MoscowAges 18 years+ - NCT07062354Enrolling by invitationPhase 2
Study of amivantamab plus chemo for head and neck cancer
This trial tests a new drug (amivantamab) combined with two chemotherapy drugs (carboplatin and paclitaxel) for people with head and neck cancer that has spread or come back after treatment and cannot be removed by surgery. This study aims to see if this combination can help shrink tumors.
Tucson, ArizonaAges 18 years+
Hear when a new Locally Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 3,558 recruiting locally advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.